PharmaCyte Biotech, Inc. (PMCB)
Nasdaq: PMCB · Biological Products, (No Diagnostic Substances) · Las Vegas, NV · filing with the SEC since 2001
Who owns PharmaCyte Biotech, Inc.
As filed with the SECHolders of 5% or more
1
Ayrton Capital LLC holds 9.9% of Common Stock, $0.0001 par value, as its SCHEDULE 13G/A filed Feb 13, 2025 says.
Directors and officers
5
report now, of 15 people on the record since 2021. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 1 named at left.
Holders of 5% or moreshare of the class, as filed
Ayrton Capital LLC
SCHEDULE 13G/A · filed Feb 13, 2025 · Common Stock, $0.0001 par value
Mitchell P. Kopin
SCHEDULE 13G/A · filed Feb 13, 2026 · Common Stock, $0.0001 par value per share · reported falling below 5%, from 9.99% in Nov 7, 2025
What PMCB reports owning in othersstakes of 5% or more, and other ties
Q/C Technologies, Inc. QCLS
SCHEDULE 13D/A · filed Nov 18, 2025 · Common Stock, par value $0.001 per share
Femasys Inc. FEMY
SCHEDULE 13G · filed Mar 18, 2026 · Common Stock, par value $0.0001 per share
3 subsidiaries in 3 countries, from the list filed with the 10-K filed Jul 29, 2026.
Insider tradesForm 4
0sales
6purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$100,000bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window2 of 15 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Silverman Joshua | CEO and President | 0 | $0 | 0 | 3 | $100,000 |
| Schechter Jonathan | director | 0 | $0 | 0 | 3 | $0 |